title: [Uveitic macular edema and the pharmacotherapy].
abstract: Macular edema represents a major cause of visual loss in uveitis and its adequate management is crucial for the maintenance of useful vision in patients with uveitis. Corticosteroid is the first choice for UME treatment.Long term and sustained release implantation is the newest administration for medical therapy. The immunosuppressant such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil can be used specially for chronic and intractable UME. Moreover, these years, some newly developed biological agents, for example, anti-VEGF, interferon-α, anti-TNF and acetazolamide will provide new options for UME pharmacotherapy.
authors.affiliation: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Xinshu
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China. Email: meifen_zhang@hotmail.com.
authors.forename: Meifen
authors.initials: M
authors.lastname: Zhang
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D000068258:Bevacizumab; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008727:Methotrexate / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha; D014605:Uveitis / Q000150:complications*; D014786:Vision Disorders / Q000209:etiology / Q000517:prevention & control
chemical_list: D000305:Adrenal Cortex Hormones; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000068258:Bevacizumab; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D000086:Acetazolamide; D008727:Methotrexate